National lipid expert faculty will discuss the incidence of and diagnostic criteria for statin intolerance, explain the mechanistic rationale for lowering LDL-C through nonstatin therapies, explore novel targets and treatment pathways, and apply the 2018 AHA/ACC Cardiology Cholesterol Guidelines. Learners will have gain practical clinical perspectives during expert case study discussions, including how new treatment options may fit into the current therapeutic landscape.

Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 11/03/2020, and they are subject to change as new information is published.

Learning Objectives

  • Discuss residual atherosclerotic cardiovascular disease (ASCVD) risk, including increased risk among patients with familial hypercholesterolemia (FH) or statin intolerance.
  • Apply recommendations from the 2018 American Heart Association (AHA)/American College of Cardiology (ACC)/Multisociety Cholesterol Guideline for managing hypercholesterolemia in patients for whom the response to maximally tolerated statin monotherapy may be inadequate.
  • Assess the clinical trial data supporting new LDL-C-lowering therapies.
  • Articulate the potential role of emerging non-statin drug therapies in the management of patients with hypercholesterolemia, including those with FH or others in whom the response to maximally tolerated statin monotherapy may be inadequate.


Kevin Maki, PhD, CLS, FNLA, FTOS, FACN

Midwest Biomedical Research a 
Division of MB Clinical Research and Consulting LLc.
Indiana University School of Public Health 
Bloomington, IN


Christie M. Ballantyne, MD, FACP, FACC

Professor of Medicine, Molecular & Human Genetics, and Molecular Physiology & Biophysics
Chief of Cardiology & Cardiovascular Research
Director, Center for Cardiometabolic Disease Prevention
Baylor College of Medicine
Houston, TX


The following relevant financial relationships have been disclosed by faculty.

Kevin C. Maki, PhD, CLS, FNLA, FTOS, FACN: Advisory Board and Consultant for Matinas Biopharma, Acasti Pharmaceuticals, and 89BIO. Consultant for Novo Nordisk and Eli Lilly. Contracted Research for Atinas Biopharma.

Christie M. Ballantyne, MD, FACP, FACC: 
Consultant and Grant/Research Support for Amgen, Esperion, Novartis, Regeneron, and Roche Diagnostic. Grant/Research Support for Akcea. Consultant for Althera, Amarin, Arrowhead, AstraZeneca, Biotech, Corvidia, Genentech, Gilead, Matinas BioPharma, New Amsterdam, Novo Nordisk, Pfizer, and Sanofi-Synthelabo. 

Peter Libby, MD (Moderator):
Research support for Novartis. Advisory Board for Amgen; Corvidia Therapeutics; DalCor Pharmaceuticals; Kowa Pharmaceuticals; Olatec Therapeutics; Medimmune; Novartis; and XBiotech, Inc. Dr. Libby declines personal compensation, but has competing interests, as follows: Consultant for Amgen; AstraZeneca; Baim Institute; Beren Therapeutics; Esperion Therapeutics; Genentech; Kancera; Kowa Pharmaceuticals; Medimmune; Merck & Co. Inc.; Norvo Nordisk Inc.; Novartis; Pfizer; and Sanofi-Regeneron.

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

MOC Credit Information

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.


Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Pri-Med Institute and  Integrity CE. Pri-Med Institute is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 040308.

Designation Statement

This program has been approved for 1.25 contact hours of continuing education, which includes 1.25 hours of pharmacology.

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 4 out of the 5 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen. For PAs, the NCCPA accepts for Category 1 CME credit activities designated for AMA PRA Category 1 Credit.

Commercial Supporter

Esperion Therapeutics, Inc.

Education Partner

Integrity CE

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.